The integration into Rightway's modern PBM combines the transparent pricing of Cost Plus Drugs with Rightway's signature member experience, granting members direct access to the pharmacy.
Mark Cuban's drug company, Cost Plus Drugs, has added healthcare company Rightway to its network. This marks the first time a Pharmacy Benefit Manager (PBM) has added the pharmacy to its network.
This relationship grants members of Rightway's PBM direct access to all medications available through Cost Plus Drugs, according to a news release.
Rising pharmacy costs are one of the fastest-growing components employers are seeing within their companies. PBMs are leaving employers and patients with few options to curb rising costs.
Cost Plus Drugs has built a parallel supply chain, sidestepping the limitations of the current PBM landscape altogether and unlocking an unprecedented level of transparency, flexibility and availability for consumers to fill their generic prescriptions. The prices at Cost Plus Drugs are at cost with a 15% markup. Prescriptions are delivered by mail, further lowering the cost per pill as mail-order medications are dispensed in greater quantities.
The integration into Rightway's modern PBM combines the transparent pricing of Cost Plus Drugs with Rightway's signature member experience, granting members direct access to the pharmacy from within the Rightway mobile app.
"Rightway's relationship with Cost Plus Drugs demonstrates our commitment to making it as easy as possible for members to get the absolute lowest price available for their prescriptions," said Scott Musial, Chief Pharmacy Officer of Rightway, in the release. "Cost Plus Drugs offers some of the lowest prices in the market. It enables Rightway to step away from the traditional supply chain, offering our members greater choice, lowering their spending, and giving them back time they'd spend at the pharmacy. Entrants like Cost Plus Drugs are welcome warriors in the battle against sky-high drug prices."
Breaking Down Health Plans, HSAs, AI With Paul Fronstin of EBRI
November 19th 2024Featured in this latest episode of Tuning In to the C-Suite podcast is Paul Fronstin, director of health benefits research at EBRI, who shed light on the evolving landscape of health benefits with editors of Managed Healthcare Executive.
Listen
A Motor Neuron Mystery Points to New Potential SMA Treatment Targets
December 20th 2024Some muscles are resistant to the loss of motor neurons seen in patients with spinal muscular atrophy, and new research has discovered that even in muscles that appeared resistant to SMA, subtle changes had occurred at the cellular level.
Read More
In this latest episode of Tuning In to the C-Suite podcast, Briana Contreras, an editor with MHE had the pleasure of meeting Loren McCaghy, director of consulting, health and consumer engagement and product insight at Accenture, to discuss the organization's latest report on U.S. consumers switching healthcare providers and insurance payers.
Listen